We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

The US National Institutes of Health has decided not to fund full-scale clinical trials of the leading AIDS vaccine in its pipeline.

At a conference in Seattle, United States, this week, 60 investigators who have been evaluating the vaccine in a midsize human study learned that an interim analysis showed weaker-than-hoped-for immune responses against HIV.

Researchers had pinned high hopes on the vaccine, a concoction made by the Franco-German pharmaceutical company Aventis Pasteur that has HIV genes stitched into a harmless bird virus, canarypox.

Reference: Science 295, 1616 (2002)